New Study Finds Publication Bias Among Trials Submitted To FDA A quarter of drug trials submitted in support of new drug applications to the US Food and Drug Administration (FDA) remain unpublished five years after the fact, says new research published in the open access journal PLoS
Medicine.
Source: www.medicalnewstoday.comMaking Male Circumcision A Top-Tier HIV Prevention Strategy With $18.5 Million Grant Male circumcision is gaining recognition as a fundamental practice for limiting the spread of HIV across sub-Saharan Africa. Three conclusive studies conducted in African countries, including Kenya, have shown that becoming circumcised dramatically reduces a man's chances of acquiring HIV from an infected woman. The challenge now is to transform this clinical knowledge into a public-
health strategy that can save millions of lives.
Source: www.medicalnewstoday.comExelixis And Bristol-Myers Squibb To Co-Develop XL413, A Selective Cdc7 Inhibitor Exelixis, Inc. (Nasdaq:EXEL) today announced that Bristol-Myers Squibb Company (NYSE:BMY) has exercised its option to develop and commercialize Exelixis' investigational new drug (IND) candidate XL413, a selective inhibitor of Cdc7. Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL413 by Bristol-Myers Squibb entitles Exelixis to a milestone payment of $20 million.
Source: www.medicalnewstoday.comHealth Tip: What to Eat During Morning Sickness Title:
Health Tip: What to Eat During Morning Sickness
Category:
Health News
Created: 11/25/2008 2:00:00 AM
Last Editorial Review: 11/25/2008
Source: www.medicinenet.comRegulation Award At National Business Awards The
Medicines and
Healthcare products Regulatory Agency (MHRA) is proud to announce winning the Better Regulation Award at the National Business Awards on Tuesday 18 November. The Better Regulation of
Medicines Initiative - BROMI - was set up to look at how administrative burdens can be reduced while maintaining high levels of patient safety. Working with industry, Governmental and
health professional stakeholders real progress has been made.
Source: www.medicalnewstoday.comSchering Plough Provides Update On Boceprevir Clinical Development And Introduces Potent Next Generation Oral HCV Protease Inhibitor Schering-Plough Corporation (NYSE: SGP) provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 PM
